Trial Profile
Toxicity OF Fluoropyrimidines: A Comparative Study of the Cardiotoxicity of capEcitabine and tEysuno
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Capecitabine; Oxaliplatin
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms TOFFEE
- 24 Oct 2023 Results assessing the comparision of cardiotoxicity of capecitabine and S-1 presented at the 48th European Society for Medical Oncology Congress.
- 11 May 2023 Status changed from active, no longer recruiting to completed.
- 16 Dec 2020 This trial is completed in UK (Global End Date: 08 Oct 2020), according to European Clinical Trials Database record.